Treatment of Sample Clauses

Treatment of. SHARES Section 2.1 Effect on the Capital Stock of SCANA.........................3 Section 2.2 Effect on the Capital Stock of PSNC of the Second Merger.....7 Section 2.3
Treatment of. Stress management;  Weight control and other conditions not attributable to a Mental Illness as defined herein;  Sexual disorders;  Organic disorders and syndromes;  Learning disabilities or mental retardation or any Severe Mental Illness as defined in the EOC and otherwise covered under the Severe Mental Illness Covered Services section. For purposes of this Exclusion, Counseling and other forms of cognitive and behavioral therapy is excluded in connection with the treatment of Attention Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD). This section is not meant to exclude an evaluation for a diagnosis of ADD or ADHD, or to exclude any corresponding outpatient prescription drugs (if otherwise available under the outpatient Prescription Drug Benefit Rider if applicable to your Plan) when prescribed by a treating Plan Provider, nor is this meant to exclude an evaluation for the diagnosis of any other co-morbid issues.
Treatment of. Each Installment as a Separate Payment. For purposes of applying the provisions of Code Section 409A to this Agreement, each separately identified amount to which the Executive is entitled under this Agreement shall be treated as a separate payment. In addition, to the extent permissible under Code Section 409A, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments.
Treatment of. claims” Each Chargor hereby agrees not to assert or enforce (whether by or in a legal or equitable proceeding or otherwise) any, “claims” (as defined in section 101(4) of the United States Bankruptcy Code) against any other Chargor, whether arising under any applicable law or otherwise, to which the Chargor is or would be entitled. It is hereby acknowledged by the Security Trustee that this Clause 14.8 does not restrict the right of any Chargor to assert or enforce any “claims” against any other Chargor to the extent that such “claims” arise after all the Chargors have been released from all their respective obligations and liabilities hereunder.
Treatment of. Bambusa vulgaris in Ghana after harvesting 9
Treatment of istisna sukuk with parallel istisna
Treatment of salam and related contracts Under a salam contract, an Islamic banking business firm is exposed to market risk after the firm has paid the purchase price to the seller and before the purchased commodity is sold and delivered to a buyer.Table 6.7.4A Market risk capital charge for salam without parallel salamstage of contract capital charge firm has paid purchase price to salam customer (seller) 15% on the long position of salam exposures firm has received purchased commodity but has not sold and delivered the commodity to a buyer Table 6.7.4B Market risk capital charge for salam with parallel salamstage of contract capital charge firm has paid purchase price to salam customer (seller) 15% on the net position (that is, after netting of salam exposures against parallel salam exposures) plus 3% on the gross position (that is, the sum of the salam exposures and parallel salam exposures) firm has received purchased commodity but has not sold and delivered the commodity to a buyer Note The parallel salam does not extinguish the requirement for capital from the first salam contract.
Treatment of. Individuals who experience rapid weight loss sometimes ***. Subjects who develop symptoms of *** need not be discontinued from therapy. These subjects should be assessed clinically and with appropriate laboratory testing ***. Subjects found to be *** may be ***, as appropriate.
Treatment of. S. Aureus Infections. This patent family relates to the use of antibodies (Abs) which specifically bind interleukin-1α (IL-1α) for treating S. aureus bloodstream infections in human patients. As of December 31, 2020, XBiotech has one pending US application. Unless extended, patents in this family expire in 2038. XBiotech has licensed exclusive rights to the intellectual property described below.
Treatment of. Subjects who *** need not be discontinued from therapy. These subjects should be assessed clinically and with laboratory testing ***. Following evaluation, subjects found to be *** may be ***, as appropriate.